Healthcare resource utilization associated with intermittent oral corticosteroid prescribing patterns in asthma.
dc.contributor.author | Tran, TN | |
dc.contributor.author | Heatley, H | |
dc.contributor.author | Bourdin, A | |
dc.contributor.author | Menzies-Gow, A | |
dc.contributor.author | Jackson, DJ | |
dc.contributor.author | Maslova, E | |
dc.contributor.author | Chapaneri, J | |
dc.contributor.author | Henley, W | |
dc.contributor.author | Carter, V | |
dc.contributor.author | Chan, JSK | |
dc.contributor.author | Ariti, C | |
dc.contributor.author | Haughney, J | |
dc.contributor.author | Price, D | |
dc.date.accessioned | 2024-08-14T08:50:24Z | |
dc.date.issued | 2024-06-21 | |
dc.date.updated | 2024-08-14T07:39:57Z | |
dc.description.abstract | PURPOSE: Oral corticosteroid (OCS) use for asthma is associated with considerable healthcare resource utilization (HCRU) and costs. However, no study has investigated this in relation to patterns of intermittent OCS prescription. METHODS: This historical UK cohort study used primary care medical records, linked to Hospital Episode Statistics, from 2008 to 2019, of patients (≥4 years old) with asthma prescribed intermittent OCS. Patients were categorized by OCS prescribing pattern (one-off [single], less frequent [≥90-day gap] and frequent [<90-day gap]) and matched 1:1 (by sex, age and index date) with people never prescribed OCS with/without asthma. HCRU (reported as episodes, except for length of hospital stay [days] and any prescription [records]) and associated costs were compared between intermittent OCS and non-OCS cohorts, and among intermittent OCS prescribing patterns. RESULTS: Of 149,191 eligible patients, 50.3% had one-off, 27.4% less frequent, and 22.3% frequent intermittent OCS prescribing patterns. Annualized non-respiratory HCRU rates were greater in the intermittent OCS versus non-OCS cohorts for GP visits (5.93 vs 4.70 episodes, p < 0.0001), hospital admissions (0.24 vs 0.16 episodes, p < 0.0001), and length of stay (1.87 vs 1.58 days, p < 0.0001). In the intermittent OCS cohort, rates were highest in the frequent prescribing group for GP visits (7.49 episodes; p < 0.0001 vs one-off), length of stay (2.15 days; p < 0.0001) and any prescription including OCS (25.22 prescriptions; p < 0.0001). Mean per-patient non-respiratory related and all-cause HCRU-related costs were higher with intermittent OCS than no OCS (£3902 vs £2722 and £8623 vs £4929, respectively), as were mean annualized costs (£565 vs £313 and £1526 vs £634, respectively). A dose-response relationship existed; HCRU-related costs were highest in the frequent prescribing cohort (p < 0.0001). CONCLUSION: Intermittent OCS use and more frequent intermittent OCS prescription patterns were associated with increased HCRU and associated costs. Improved asthma management is needed to reduce reliance on intermittent OCS in primary care. | en_GB |
dc.description.sponsorship | AstraZeneca | en_GB |
dc.format.extent | 573-587 | |
dc.format.medium | Electronic-eCollection | |
dc.identifier.citation | Vol. 17, pp. 573-587 | en_GB |
dc.identifier.doi | https://doi.org/10.2147/JAA.S452305 | |
dc.identifier.uri | http://hdl.handle.net/10871/137157 | |
dc.identifier | ORCID: 0000-0001-6273-2619 (Henley, William) | |
dc.language.iso | en | en_GB |
dc.publisher | Dove Press | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/38919734 | en_GB |
dc.relation.url | https://opcrd.co.uk/our-database/data-requests/ | en_GB |
dc.rights | © 2024 Tran et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). | en_GB |
dc.subject | asthma | en_GB |
dc.subject | costs | en_GB |
dc.subject | healthcare resource utilization | en_GB |
dc.subject | intermittent | en_GB |
dc.subject | oral corticosteroids | en_GB |
dc.title | Healthcare resource utilization associated with intermittent oral corticosteroid prescribing patterns in asthma. | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2024-08-14T08:50:24Z | |
dc.identifier.issn | 1178-6965 | |
exeter.place-of-publication | New Zealand | |
dc.description | This is the final version. Available from Dove Press via the DOI in this record. | en_GB |
dc.description | Data Sharing Statement: The dataset supporting the conclusions of this article was derived from the Optimum Patient Care Research Database (www.opcrd.co.uk). The authors do not have permission to give public access to the study dataset; researchers may request access to OPCRD data for their own purposes. Access to OCPRD can be made via the OCPRD website (https://opcrd.co.uk/our-database/data-requests/) or via the enquiries Email info@opcrd.co.uk. | en_GB |
dc.identifier.journal | Journal of Asthma and Allergy | en_GB |
dc.relation.ispartof | J Asthma Allergy, 17 | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/ | en_GB |
dcterms.dateAccepted | 2024-05-17 | |
dc.rights.license | CC BY-NC | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2024-06-21 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2024-08-14T08:47:33Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2024-08-14T08:50:30Z | |
refterms.panel | A | en_GB |
refterms.dateFirstOnline | 2024-06-21 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2024 Tran et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).